SCHEMBL6944165

SCHEMBL6944165

NC(=O)c1ccc(N[C@H]2CC[C@H](O)CC2)c(C(=O)NCc2ccc3c(c2)OCO3)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
HSP90AA1 P07900 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
MMP13 P45452 1/20 0.49
NPC1 O15118 1/20 0.48
HSD17B10 Q99714 1/20 0.47
PKM P14618 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
TSHR P16473 1/20 0.46
HPGD P15428 2/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6944157 1.00 ALDH1A1 (0.51) ALDH1A1HSP90AA1TDP1MEN1KMT2A
SCHEMBL6940176 0.84 KDM4E (0.46) ALDH1A1HSP90AA1TDP1MEN1KMT2A
SCHEMBL6940177 0.84 KDM4E (0.46) ALDH1A1HSP90AA1TDP1MEN1KMT2A
SCHEMBL6939374 0.83 MAPT (0.60) ALDH1A1TDP1MEN1KMT2ALMNA
SCHEMBL6941990 0.83 MAPT (0.60) ALDH1A1TDP1MEN1KMT2ALMNA
SCHEMBL6939369 0.83 MAPT (0.60) ALDH1A1TDP1MEN1KMT2ALMNA
SCHEMBL6946662 0.79 TDP1 (0.54) ALDH1A1HSP90AA1TDP1MEN1KMT2A
SCHEMBL6946670 0.79 TDP1 (0.54) ALDH1A1HSP90AA1TDP1MEN1KMT2A
SCHEMBL6942060 0.79 MEN1 (0.57) ALDH1A1MEN1KMT2ALMNAMAPK1
SCHEMBL6941355 0.78 MAPT (0.53) ALDH1A1TDP1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A ALDH1A1 253/4885HSP90AA1 1232/4885TDP1 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.